Associated Banc Corp reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.7% during the 4th quarter, HoldingsChannel reports. The fund owned 24,232 shares of the medical research company’s stock after selling 408 shares during the quarter. Associated Banc Corp’s holdings in Thermo Fisher Scientific were worth $4,601,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Capital Research Global Investors raised its position in Thermo Fisher Scientific by 29.8% during the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Thermo Fisher Scientific by 2,058.1% in the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock valued at $408,620,000 after purchasing an additional 2,233,522 shares during the last quarter. Veritas Asset Management LLP increased its holdings in shares of Thermo Fisher Scientific by 44.1% in the third quarter. Veritas Asset Management LLP now owns 3,503,259 shares of the medical research company’s stock valued at $662,817,000 after purchasing an additional 1,072,500 shares during the last quarter. Meritage Group LP acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at $201,383,000. Finally, Capital World Investors increased its holdings in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock valued at $2,051,721,000 after purchasing an additional 671,637 shares during the last quarter. 86.11% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have commented on TMO. Barclays upped their price objective on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Bank of America upped their price objective on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Leerink Swann reiterated an “outperform” rating and issued a $239.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday, February 1st. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective on the stock in a report on Tuesday, October 31st. Finally, Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Two research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $220.50.

Thermo Fisher Scientific Inc. (NYSE:TMO) opened at $204.51 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.35 and a quick ratio of 0.92. Thermo Fisher Scientific Inc. has a one year low of $151.74 and a one year high of $226.44. The company has a market cap of $81,580.00, a PE ratio of 36.52, a P/E/G ratio of 1.47 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the prior year, the company posted $2.41 earnings per share. Thermo Fisher Scientific’s revenue was up 22.1% compared to the same quarter last year. research analysts anticipate that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is 10.71%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now directly owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen Williamson sold 5,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $209.26, for a total transaction of $1,046,300.00. Following the sale, the chief financial officer now owns 30,741 shares in the company, valued at $6,432,861.66. The disclosure for this sale can be found here. Insiders sold 144,327 shares of company stock worth $28,680,042 over the last 90 days. 0.49% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/associated-banc-corp-cuts-stake-in-thermo-fisher-scientific-inc-tmo/1862533.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.